Skip to main content

FDA Approves Amphastar's Nasal Spray To Fight Opioid Crisis

FDA Approves Amphastar's Nasal Spray To Fight Opioid Crisis

FDA Approves Amphastar's Nasal Spray To Fight Opioid Crisis

Introduction

Amphastar Pharmaceuticals Inc announced that the FDA had cleared its nasal spray for the emergency treatment of known or suspected opioid overdose.

According to the FDA label, the company's naloxone hydrochloride nasal spray may be supplied in one spray by intranasal administration, giving 4 mg of the medicine in adults and paediatric patients for an initial dosage. 

The approval comes as the FDA is examining applications to enable the over-the-counter use of various naloxone-based medications, including one for Emergent Biosolutions' Narcan.

Late last year, the health regulator stated that naloxone may be safe and effective for over-the-counter usage in some formulations, possibly opening the way for its nationwide use and prompting additional firms to pursue prescription-free permission.

According to federal figures, more than 106,000 persons died in the United States in 2021 from drug-related overdoses.

Earlier this month, Emergent BioSolutions Inc., the maker of Narcan, a nasal spray form of naloxone, said that the US Food and Drug Administration had granted its application for an over-the-counter version of its popular opioid-reversal nasal spray.

Both of these nasal sprays would help to curb the opioid problem across the country.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!